TrialBreast cancer research and treatment2016

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Z A Nahleh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.